The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | APR-246 combination treatments in TP53-mutant R/R NHLs
Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an upcoming Phase 1 study (NCT04419389) aiming to evaluate the efficacy and safety of APR-246 in combination with ibrutinib or a venetoclax-based therapy in patients with TP53-mutant relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Enrollment for this trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Curio Science
